Literature Review

Metabolic Therapy as an Adjunct to Conventional Cancer Treatment: A Targeted Approach

Madhu Bala[1], Jyoti Kaur[2]

[1]Assistant Professor, Deptt of Zoology and Environmental Sciences, Punjabi University Patiala Punjab (India), [2]MSc student, Deptt of Zoology and Environmental Sciences, Punjabi University Patiala Punjab (India)

How to cite this article: Madhu Bala, Jyoti Kaur. Metabolic Therapy as an Adjunct to Conventional Cancer Treatment: A Targeted Approach. International Journal of Physiology / Vol. 14 No. 1, January-June 2026.

Abstract

Context: Metabolic therapy encompasses a range of strategies that involve the utilization of metabolic inhibitors, dietary interventions, and natural compounds that modulate metabolic regulators. These methodologies exhibit promising outcomes in preclinical models and early-phase clinical trials for cancer treatment.

Objectives: To elucidate how metabolic therapy disrupts energy production in neoplastic cells while protecting normal cells.

Methods: A comprehensive literature review was conducted utilizing scientific databases.

Results: Metabolic therapy targets cancer cells' energy pathways with inhibitors like metformin and dichloroacetate, disrupting growth without harming normal cells. Dietary strategies, including the ketogenic diet, starve cancer cells and promote fat consumption. Natural compounds like curcumin and resveratrol regulate metabolic processes in cancer cells, potentially slowing tumor growth.

Discussion: Clinical trials have demonstrated encouraging outcomes with the implementation of metabolic therapies.

Conclusion: Strategic exploitation of metabolic vulnerabilities in cancer cells offers a promising avenue for effective therapeutic interventions in the battle against cancer.

Keywords: Metabolic therapy; metabolic inhibitors; dietary interventions; natural compounds; metabolic regulators.

Introduction

Cancer is a malignancy marked by uncontrolled cell growth. It is a leading global cause of death. In the U.S., One in four deaths in 2012 was due to cancer. Worldwide, cancer deaths are expected to rise to 13.2 million by 2030, mainly due to aging and

Corresponding Author: Madhu Bala, Assistant Professor, Deptt of Zoology and Environmental Sciences, Punjabi University Patiala Punjab (India).

E-mail: madhubaladhakane@gmail.com

Submission date: December 2, 2025 **Acceptance date:** January 9, 2026 **Published date: January 23, 2026**

cancer-promoting behaviors[1]. Cancer is a group of disorders marked by abnormal cell growth that can invade tissues and spread to organs. Traditional treatments like chemotherapy, radiotherapy, and surgery show varying effectiveness. However, these methods often cause significant side effects, harm healthy tissues, and lead to treatment resistance[1].

Researchers now focus on cancer cell metabolic characteristics. Cancer cell reprogramming offers new therapeutic targets unlike those in normal cells. Cancer cells prefer glycolysis for energy, even with oxygen, unlike healthy cells that use mitochondrial oxidative phosphorylation. This is known as the warburg effect. This change promotes faster growth, biomass accumulation, and increased resistance to apoptosis[2]. Scientists traditionally believe cancer arises from genetic mutations. Recent studies highlight energy production's role in cancer cells. This shift is captured in metabolic therapy for cancer[3]. Metabolic therapy targets the unique energy metabolism of cancer cells. Unlike chemotherapy or radiation, it disrupts cancer's altered biochemical pathways while preserving normal tissue[3]. Aberrant energy metabolism is now a cancer hallmark, crucial for tumor initiation, progression, and survival. This metabolic reprogramming drives the disease, not just a consequence. Targeting metabolic pathways offers a selective strategy against cancer. Cancer cells alter metabolism to support rapid growth. The Warburg Effect, identified by Otto Warburg in the 1920s, is notable. Cancer cells ferment glucose into lactate via glycolysis, even with ample oxygen, which is less efficient than oxidative phosphorylation in normal cells[4]. This shift allows cancer cells to quickly generate energy, produce biomass intermediates, maintain redox balance, and evade apoptosis. These changes make cancer metabolism a compelling therapeutic target[5]. Cancer cells exploit metabolic pathways for energy and growth. This reprogramming is key in tumorigenesis. Figure 1 shows three main metabolic phenotypes in cancer cells: glycolytic, oxidative phosphorylation (OXPHOS), and combined. The glycolytic phenotype relies on glucose catabolism via glycolysis, producing high lactate levels. It features increased glucose uptake, rapid growth, and reduced mitochondrial function. In contrast, OXPHOS cells use mitochondrial respiration, showing high oxygen consumption, low lactate production, and better mitochondrial function, but slower growth. The combined phenotype uses both glycolysis and OXPHOS, granting metabolic flexibility. These cells adapt to various microenvironments and are linked to increased metastasis and treatment resistance. This adaptability complicates targeting cancer metabolism therapeutically [6].



Figure 1: Metabolic patterns and their continuous transition in cancer cells[6].

The objective of the present review is to elucidate that metabolic therapy disrupts the aberrant energy production mechanisms in neoplastic cells while sparing normal cells. Strategies encompass the utilization of metabolic inhibitors (e.g., metformin, dichloroacetate), dietary interventions (e.g., ketogenic

diet, caloric restriction), and natural compounds (e.g., curcumin, resveratrol) that modulate pivotal metabolic regulators. These methodologies have demonstrated promising outcomes in both preclinical models and early-phase clinical trials [7,5].

Metabolic therapy encompasses a variety of interconnected strategies, which include:

Pharmacological targeting of metabolism:

Metformin: Metformin is a widely utilized pharmacological agent for the management of type 2 diabetes. Emerging research suggests that it may also play a role in combating cancer. Its mechanisms of action can be delineated into two primary categories[8].

a. Systemic Effects: Metformin lowers blood glucose and insulin in hyperglycemia, boosts ketone production, and inhibits cancer growth.

Cellular Effects: Metformin disrupts cancer cell mitochondria, lowers ATP, and activates AMPK, which inhibits growth and lipid synthesis, possibly causing apoptosis under stress [8].

Despite promising studies, human trials showed no significant benefits. Patient selection may influence metformin's effectiveness. Metformin is safe, cost-effective, and studied with other therapies. Tailoring treatment to tumor metabolism may enhance outcomes [9].

Dichloroacetate (DCA): Dichloroacetate (DCA) is an oral drug for various ailments. Studies show its cancer therapy by targeting mitochondria in cancer cells. Cancer cells favor glycolysis due to the Warburg effect. DCA corrects this by inhibiting PDK and promoting oxidative phosphorylation. This induces mitochondrial depolarization, increases reactive oxygen species, and can trigger apoptosis [8]. In lab studies, DCA was given to various cancer cell types, including brain, lung, and breast. Observed outcomes: apoptosis began, tumor growth slowed, energy metabolism normalized, and healthy cells remained unharmed. In animal studies, tumors regressed; PET imaging showed reduced glucose uptake in cancer cells, indicating lower metabolic activity. The left side of Figure 2 shows DCA reducing mitochondrial energy levels, while the right side shows a PET scan indicating reduced tumor size and glucose consumption post-DCA treatment, supporting that tumors became metabolically compromised [10].



Figure 2: Brain MRI showing a glioblastoma tumor and fluorodeoxyglucose (FDG-glucose) PET from the same patient [10].

DCA has been used for decades, known for its safety at proper dosages. Some patients may experience nerve pain or weakness, which resolves after stopping the medication. No cancer patients have undergone formal DCA trials. Researchers are optimistic about DCA as a future cancer treatment due to its low cost and ease of use. DCA may be effective against glioblastoma, lung, breast, prostate, and endometrial cancers [10].

2-Deoxy-D-Glucose (2-DG): In metabolic therapy for cancer, the goal is to block cancer cells' energy sources, mainly glycolysis. 2-DG mimics glucose to disrupt glycolysis, causing cell stress and death. Cancer cells are more vulnerable to this, especially in low-oxygen environments. 2-DG is key in metabolic therapy, cutting off cancer cells' energy supply. It targets abnormal glucose metabolism by inhibiting glycolytic enzymes. 2-DG-6-phosphate blocks glycolysis and ATP synthesis. Under hypoxia, this inhibition causes cell cycle arrest and death. 2-DG disrupts protein N-glycosylation, inducing ER stress and enhancing cell death. It boosts chemotherapy and radiotherapy by increasing oxidative stress and impairing DNA repair. Its ability to cross the blood-brain barrier is promising for brain tumors like glioblastoma. Despite pharmacokinetic challenges, new analogs like WP1122 are being developed to enhance clinical potential [11].

Dietary Interventions as Metabolic Therapy

Ketogenic diet: Some tumors, like melanomas, showed inadequate responses or worsened on a ketogenic diet. Effects vary by caloric intake, fat types,

and adherence. More trials are needed for safety and efficacy across cancer types. The ketogenic diet may be a safe, cost-effective strategy to complement standard therapies. Further human studies are needed to confirm benefits and limits. The ketogenic diet restricts glucose and increases ketone bodies, which some cancer cells can't use well. Studies show tumor suppression and better outcomes with conventional therapies. Ketogenic diets involve high fat, moderate protein, and low carbs, shifting energy to fatty acid oxidation. The liver converts excess acetyl-CoA into ketone bodies for energy. This metabolic shift aims to deprive cancer cells of glucose [8].

Normal cells, especially in the brain and muscle, adapt to ketone metabolism for ATP generation. Cancer cells lack enzymes to use ketones, making them vulnerable to ketogenic conditions. Autogenicdiet shows promise in treating brain tumors like retinoblastoma multiforme. Studies demonstrate metabolic benefits in cancer patients on low-carb diets[8].

Key variants:

- Classic KD: 4:1 ratio (fat to carbs + protein).
- Modified Atkins Diet (MAD): Less restrictive, more adaptable.
- Medium-chain triglyceride (MCT) KD: Utilizes MCTs to enhance ketone production.
- Low-carbohydrate high-fat diets (LCHF): A broader category, occasionally used interchangeably (Figure 3) [12].



Figure 3: The compositional features of the classic KD and its variants [12].

The ketogenic diet seemingly engenders a detrimental metabolic milieu for numerous cancer types, rendering it a promising adjunctive therapeutic strategy. It possesses the potential to augment the efficacy of conventional cancer treatments, enhance quality of life, and provide a cost-effective, low-toxicity intervention. Nevertheless, further rigorously controlled clinical trials are imperative prior to their routine application [13, 14].

Fasting and Caloric Restriction: Fasting involves abstaining from food for 3-5 days, known as short-term fasting (STF), causing metabolic changes that combat cancer. During fasting:

- Blood sugar decreases

- Insulin levels drop

- IGF-1 hormone, which promotes cancer cell growth, decreases

- Ketone bodies increase as an energy source for healthy cells [8].

Physiological changes hinder cancer cells but protect healthy ones. Fasting slows healthy cells and boosts defenses. Cancer cells grow, becoming more vulnerable to treatment. Fasting reduces chemotherapy side effects and enhances treatment efficacy. Caloric restriction lowers cancer risk and inhibits tumor growth. Complete fasting is hard, so researchers created the Fasting-Mimicking Diet as a safer option. Fasting and caloric restriction slow cancer growth and improve treatment. These methods are being tested in clinical trials for future cancer protocols [15].

Fasting-Mimicking Diet (FMD): The Fasting-Mimicking Diet (FMD) mimics fasting benefits with a low-calorie, low-protein ketogenic diet for 4-5 days monthly. FMD induces a fasting mode, causing

metabolic changes. Research shows FMD lowers blood glucose, reduces insulin and IGF-1, and boosts ketone production. These changes may hinder cancer growth, improve chemotherapy, and protect normal cells. Animal studies suggest FMD slows tumor growth, enhances chemotherapy, and improves survival rates with fewer side effects than standard protocols.

Human studies show FMD is well-tolerated, leading to weight loss, better metabolic health, and reduced chemotherapy side effects in some cancer patients, including breast cancer. FMD is easier than complete fasting, especially for weak individuals or those undergoing cancer treatment. It doesn't require total food abstinence, making it safer for most patients. More clinical trials are needed to assess FMD's efficacy across cancer types. The fasting-mimicking diet is a promising strategy to fight cancer, protect healthy cells, and enhance treatment efficacy, offering a more comfortable alternative to prolonged fasting [8].

Role of Natural Compounds in Metabolic Therapy

Curcumin: Curcumin from turmeric fights cancer by altering metabolism. Cancer cells use glycolysis for energy even with oxygen [16]. Curcumin's mechanisms are:

1. Inhibition of Glycolysis and Reduced Glucose Utilization: Curcumin blocks glucose breakdown in cancer cells, lowering energy and slowing growth. It downregulates glycolytic enzymes like HK2, PKM2, and LDHA, reducing glucose use and lactate production [17].

2. Mitochondrial Regulation: It boosts mitochondrial function, enhancing oxidative phosphorylation and reducing the Warburg effect.

3. Suppression of HIF-1α: Curcumin hinders HIF-1α, which helps cancer cells survive low oxygen and increases glycolysis, thus impeding growth.

4. Activation of AMPK: Curcumin activates AMPK, stopping cell proliferation due to low energy and curbing cancer growth.

5. Reduction of Inflammation and Oxidative Stress: Curcumin's anti-inflammatory properties create an inhospitable environment for tumors [16].

2. Resveratrol: Resveratrol in grapes, berries, and peanuts fights inflammation, acts as an antioxidant, and protects heart health. It shows promise in cancer prevention by inhibiting cell growth and enhancing chemotherapy. Resveratrol protects DNA, inhibits carcinogens, and detoxifies harmful substances. It slows cancer progression by blocking cell division and activating repair proteins. It also hinders metastasis by impeding enzymes and reducing blood vessel formation [18].

Resveratrol blocks cancer cell changes that promote migration and invasion. It inhibits the proteins NF-κB and STAT3, which help cancer evade apoptosis and develop resistance. By blocking these signals, resveratrol enhances tumor-fighting ability. It boosts chemotherapy efficacy and can reverse treatment resistance. Resveratrol reduces tumor size and quantity, inhibits metastasis, promotes cell death, and lowers inflammation. These findings support resveratrol's use in future cancer therapies. Resveratrol is a powerful natural compound that prevents cancer, slows progression, inhibits spread, and enhances chemotherapy. Its diverse action and low toxicity make it a promising cancer prevention and treatment option [18].

Comparison Between Metabolic Theory and Somatic Mutation Theory

Contrast between Somatic Mutation Theory (SMT) and Mitochondrial Metabolic Theory (MMT)[19]. SMT: Cancer arises from mutations. MMT: Cancer results from dysfunctional mitochondria. Dysfunctional mitochondria cause reliance on fermentation for energy. Most cancer cells depend on fermentation despite oxygen. Cancer may be a metabolic disorder. Modulating glucose and glutamine metabolism is an alternative to chemotherapy.Table1 provides a comparative analysis of both theories.

Table 1: Comparison between somatic mutation theory (SMT) and mitochondrial metabolic theory (MMT). [20]

Criteria	Somatic Mutation Theory (SMT)	Mitochondrial Metabolic Theory (MMT)
Core Hypothesis	Cancer is caused by random mutations in nuclear DNA (oncogenes and tumor suppressor genes).	Cancer arises from defects in mitochondrial function, particularly oxidative phosphorylation (OxPhos).
View on Mitochondria	Mitochondria are secondary to mutations; not the primary cause of cancer.	Mitochondria are central to cancer origin; dysfunctional respiration forces cells to rely on fermentation (glycolysis).
Experimental Evidence	Based on genomic sequencing of tumors, thousands of mutations.	Supported by cybrid experiments; normal mitochondria can suppress tumorigenesis even with mutated nuclei.
Mutation Role	Driver mutations are causal; cancer is a genetic disease.	Mutations are by-products of mitochondrial dysfunction and reactive oxygen species (ROS) damage.
Explains Tumor Heterogeneity?	It struggles to explain this consistently; different cancers have different mutations.	Yes — mitochondrial dysfunction leads to a common metabolic phenotype (fermentation), regardless of genetics.
Therapeutic Approach	Target gene mutations (e.g., targeted drugs, immunotherapy, chemotherapy).	Target metabolism — e.g., ketogenic diets, glucose restriction, drugs that impair fermentation.
Strengths	Strongly backed by large-scale genomics data; mutation catalogs.	Explains phenomena like tumor regression, dormancy, and treatment resistance more holistically.
Weaknesses	Fails to consistently explain tumor behavior across cancers.	Still under evaluation, metabolic therapies are not yet mainstream.

Case Studies

Case 1 Prolonged Management of Cerebral Neoplasia Utilizing Ketogenic Metabolic Therapy [20]**:**This study supports the metabolic theory of cancer by showing that a ketogenic diet can slow tumor growth independent of standard treatments. It highlights how cellular metabolism changes impact cancer, suggesting metabolic dysfunction drives cancer more than genetics. In 2021, Seyfried and colleagues reported a patient with aggressive brain cancer who chose ketogenic therapy over chemotherapy and radiation. The therapy, high in fat and low in carbs, induces ketosis, using ketones for energy instead of glucose. This could starve cancer cells while sparing normal ones. The patient's tumor grew slower than usual over 80 months on this therapy, supporting cancer as a metabolic disorder. This case suggests dietary interventions could be a promising approach for certain brain tumors, providing evidence for the metabolic theory of cancer.

Significance of the case study:

- Shows long-term viability of metabolic therapy without conventional treatments.

- Supports targeting cancer metabolism to slow tumor progression.

- Highlights the promise of ketogenic diets as a safe, effective therapy.

- Provides evidence for the mitochondrial metabolic theory of cancer.

- Emphasizes the need for personalized, metabolism-focused treatment.

Case 2 Role of the Nucleus and Mitochondria in the Origin of Tumors: This experiment shows that nuclear genomic defects can't solely explain tumor genesis, but functional mitochondria can inhibit it (Figure 4). Normal cells in green have normal gene expression and OxPhos function. Tumor

cells in red exhibit abnormal morphology due to compromised OxPhos function. Normal cells grow regulated manner; tumor cells grow unregulated manner. Transferring a tumor cell nucleus into normal cytoplasm yields regulated normal cells despite genomic defects. Transferring a normal cell nucleus into tumor cytoplasm results in necrotic or dysregulated tumor cells.[20]



Figure 4. Role of the nucleus and mitochondria in the origin of tumors [20].

Warburg effect: A metabolic hallmark of cancer

The Warburg Effect, a key concept in cancer metabolism, was described by Otto Warburg in the 1920s. It explains how cancer cells convert glucose to lactate via aerobic glycolysis, even in oxygen-rich environments that support oxidative phosphorylation. This shift promotes rapid tumor growth and survival. Unlike normal cells that use glycolysis and oxidative phosphorylation, cancer cells convert pyruvate to lactate even with oxygen present. This less efficient process yields only 2 ATP per glucose but allows cancer cells to quickly process glucose for growth needs (Figure 5).



Figure 5. Schematic diagram of aerobic glycolysis in cancer cells compared with normal cells.[21]

Mitochondrial dysfunction in cancer cells impairs oxidative phosphorylation, leading to glycolysis for ATP. This shift creates a loop between GAPDH and LDH, where GAPDH overactivity causes NADH accumulation, driving LDH to convert pyruvate into lactate. This loop depletes pyruvate, promotes lactate buildup, increases oxidative stress, and aids carcinogenesis. The Warburg effect is sustained by this and worsened by hypoxia, acidification, and immune evasion [22].



Figure 6: Origin of the Warburg effect: Closed circuit between GAPDH and LDH[22].

Role of the ketogenic diet in the Warburg effect: Cancer cells use aerobic glycolysis for ATP despite oxygen - Warburg effect. Without oxygen, cells switch to anaerobic glycolysis, fermenting glucose to lactate. Cancer cells have high reactive oxygen species from a dysfunctional electron transport chain. Ketogenic diet lowers glucose and raises ketone bodies, starving cancer cells. Normal cells adapt by increasing fatty acid oxidation, producing ketone bodies for ATP. Cancer cells can't efficiently produce ATP with ketone bodies, inhibiting growth. Normal cells inhibit glycolysis with less glucose, using fatty acid oxidation for ATP. Cancer cells can't effectively produce ATP from ketones, causing energy depletion and inhibiting proliferation.



Figure 7. Scheme of cell behavior during the ketogenic diet (normal cell vs. cancer cell). [14]

Molecular mechanism behind the Warburg effect: The Warburg effect, a hallmark of cancer metabolism, is regulated by several key signaling pathways and molecular players that promote glycolysis even in the presence of oxygen (Figure 8).

PI3K/Akt/mTOR Pathway: This cascade promotes growth, survival, and glucose metabolism. Akt enhances glucose uptake and glycolysis. The mTOR complex amplifies this by increasing metabolic proteins [23].

c-Myc Oncogene: c-Myc drives growth and proliferation, often overexpressed in cancer. It activates glycolytic enzyme genes, enhancing glycolysis. c-Myc also increases reactive oxygen species, damaging mitochondria and favoring glycolysis for ATP [23].

Hypoxia-Inducible Factor-1 (HIF-1): Under hypoxia, HIF-1α is stabilized and activated, upregulating glucose transporters and glycolytic enzymes. HIF-1α induces PDK1, inhibiting pyruvate conversion to acetyl-CoA, reducing oxidative phosphorylation, and reinforcing glycolysis [23].

p53 Tumor Suppressor: p53 supports respiration and inhibits glycolysis. p53 mutations or loss in cancers shift the balance to glycolysis, promoting rapid proliferation [23].

Together, these pathways coordinate metabolic re-programming in cancer cells, reinforcing glycolysis for tumor growth and survival.



Figure 8: Molecular mechanism behind the Warburg effect. [23]

Benefits of the Warburg effect for cancer cells:

Rapid ATP production: Aerobic glycolysis boosts ATP synthesis, fueling cancer growth.

Anabolic building blocks: Glycolysis intermediates supply essential components for growth and survival.

Resistance to hypoxia: The Warburg effect allows cancer cells to produce ATP via glycolysis under low oxygen.

Tumor microenvironment modification: Lactate creates an acidic environment that promotes tumor growth and metastasis.

Thus, the Warburg effect is a metabolic reprogramming in cancer cells, enhancing energy production, growth materials, and stress resilience.

Challenges and Limitations of Metabolic Therapy for Cancer

Before it can be utilized extensively in patients, several challenges must be addressed, as elucidated below:

Tumor Metabolic Heterogeneity: A major obstacle is intra- and intertumoral metabolic heterogeneity. Tumor types and regions may use different fuels and pathways. Some cancer cells prefer glycolysis; others use glutamine or fatty acids. This diversity complicates treatment and reduces broad metabolic interventions effectiveness Tumors have unique metabolic profiles; not all cancer cells are alike. Some use glucose, while others use proteins or fats. Even within a tumor, areas may metabolize different substances. This variability makes universal treatment very challenging.[24]

Metabolic Plasticity and Adaptability: Cancer cells can switch energy sources, hindering therapies targeting one pathway. Blocking one fuel prompts cells to use alternatives, suggesting therapy may lose effectiveness over time [25].

Lack of Predictive Biomarkers: Reliable biomarkers to predict patient benefit from metabolic therapies are lacking. Not all respond well to metformin, complicating treatment personalization. No definitive method exists to identify beneficial patients. Practitioners lack dependable biomarkers for metabolic therapy responses. Some patients may not benefit from treatment [26].

Limited Clinical Data: Metabolic therapy success is mainly in animal studies and lab experiments. Few clinical trials in humans make confirming safety and efficacy difficult [15].

Resistance Development: Cancer cells adapt and develop resistance over time, limiting treatment success. They can gain resistance to metabolic inhibitors via compensatory pathways or mutations. Tumors may upregulate alternative pathways when exposed to specific inhibitors [27].

Effects on Normal Cells and Tissues: Metabolic therapies targeting cancer cells may also affect normal cells, causing toxicity and adverse effects like fatigue and gastrointestinal disturbances [28].

Strict Diets Are Hard to Follow: Many metabolic therapies require strict diets, like the ketogenic diet, which are hard for sick or fatigued patients. Decreased appetite and stress hinder adherence [29].

Influence of Tumor Microenvironment (TME): Cancer exists in a microenvironment with blood vessels and immune cells that can support survival and reduce therapy effectiveness [30].

Regulatory and Ethical Hurdles: Some metabolic interventions involve off-label medications or extreme diets, raising regulatory and ethical concerns. Long-term safety profiles of many therapies are unclear [9].

Conclusion

Cancer is a leading global health challenge, and despite advancements in surgery, chemotherapy, and radiotherapy, issues like drug resistance and treatment failure hinder long-term success. Metabolic therapy has emerged as a promising cancer treatment approach. Unlike conventional therapies, metabolic interventions target cancer cells' altered energy metabolism, primarily their glycolysis dependence, while sparing normal cells. This thesis reviewed various metabolic therapy strategies, including pharmacological agents (e.g., metformin, DCA, 2-DG), dietary interventions (e.g., ketogenic diet, fasting), and natural compounds (e.g., curcumin, resveratrol). These strategies exploit cancer cells' unique metabolic vulnerabilities, enhancing standard treatments' efficacy, reducing side effects, and improving patient outcomes. A comparative analysis of the somatic mutation theory and the mitochondrial metabolic theory was presented to deepen understanding of cancer origins. Evidence increasingly supports the mitochondrial theory, which suggests that dysfunctional mitochondria and metabolic reprogramming drive carcinogenesis. This shift opens avenues for targeted, non-toxic metabolic therapies. However, metabolic therapy faces challenges, including tumor heterogeneity, metabolic plasticity, a lack of reliable biomarkers, and few clinical trials. Nonetheless, ongoing research, precise patient stratification, and integration with conventional modalities offer encouraging prospects. In conclusion, metabolic therapy is a safe, cost-effective, and innovative complement to existing cancer treatments. Continued research and well-designed clinical trials are crucial for standardizing protocols and validating long-term efficacy. With sustained progress, metabolic therapy could become a cornerstone in future cancer management.

Acknowledgments: The authors express their profound gratitude to the Department of Zoology and Environmental Sciences at Punjabi University, Patiala, for the indispensable facilities provided.

Financial Support: This research received no external funding.

Conflict of Interest: There is no conflict of interest among the authors.

Data Availability statement: Data will be accessible through the corresponding author and will be furnished upon request.

References

1. Longo VD, Brandhorst S. Fasting and caloric restriction in cancer prevention and treatment. *Recent Results Cancer Res* 2016;241–266.
2. Warburg O. On the origin of cancer cells. *Science* 1956; 123:309–314.
3. Seyfried TN, Flores RE, Poff AM, D'Agostino DP. Cancer as a metabolic disease: implications for novel therapeutics. *Carcinogenesis* 2014; 35:515–527.
4. Seyfried TN, Shelton LM. Cancer as a metabolic disease. *Nutr Metab* 2010; 7:7.
5. Xiao Y, Yu TJ, Xu Y, Ding R, Wang YP, Jiang YZ, Shao ZM. Emerging therapies in cancer. *Cell Metab* 2023; 35:1283–1303.
6. Yang J, Shay C, Saba NF, Teng Y. Cancer metabolism and carcinogenesis. *Exp Hematol Oncol* 2024; 13:10.
7. Klement RJ, Champ CE. Calories, carbohydrates, and radiation therapy: exploiting the five R's through dietary manipulation. *Cancer Metastasis Rev* 2014; 33:217–229.
8. Vernieri C, Casola S, Foiani M, Pietrantonio F, de Braud F, Longo V. Targeting cancer metabolism: dietary and pharmacologic interventions. *Cancer Discov* 2016; 6:1315–1333.
9. Pollak M. Metformin and other biguanides in oncology. *Cancer Prev Res* 2010; 3:1060–1065.
10. Michelakis ED, Webster L, Mackey JR. Dichloroacetate as a metabolic-targeting therapy for cancer. *Br J Cancer* 2008; 99:989–994.
11. Pajak B, Siwiak E, Sołtyka M, et al. 2-Deoxy-D-glucose and its analogs: from diagnostic to therapeutic agents. *Int J Mol Sci* 2019; 21:234.
12. Zhu H, Bi D, Zhang Y, et al. Ketogenic diet for human diseases: underlying mechanisms and clinical potential. *Signal Transduct Target Ther* 2022; 7:11.
13. Weber DD, Aminzadeh-Gohari S, Tulipan J, et al. Ketogenic diet in cancer treatment. *Mol Metab* 2020; 33:102–121.
14. Talib WH, Mahmod AI, Kamal A, et al. Ketogenic diet in cancer prevention and therapy. *Curr Issues Mol Biol* 2021; 43:558–589.
15. Longo VD, Brandhorst S. Fasting and caloric restriction for reducing tumor growth. *Recent Results Cancer Res* 2016; 207:241–266.
16. Shanmugam MK, Rane G, Kanchi MM, et al. Multifaceted role of curcumin in cancer. *Molecules* 2015; 20:2728–2769.
17. Siddiqui FA, Prakasam G, Chattopadhyay S, et al. Curcumin reduces the Warburg effect via PKM2 and mTOR-HIF1α inhibition. *Sci Rep* 2018; 8:8323.
18. Ko JH, Um JY, Shanmugam MK, et al. The role of resveratrol in cancer therapy. *Int J Mol Sci* 2017; 18:2589.
19. Seyfried TN, Chinopoulos C. Mitochondrial metabolic theory vs. somatic mutation theory. *Metabolites* 2021; 11:572.
20. Seyfried TN, Shivane AG, Kalamian M, Maroon J, Mukherjee P, Zuccoli G. Ketogenic metabolic therapy for IDH1-mutant glioblastoma: case report. *Front Nutr* 2021; 8:682243.
21. Fadaka A, Ajiboye B, Ojo O, et al. Glucose metabolism in cancer. *J Oncol Sci* 2017; 3:45–51.
22. Sayad A. Biochemical origin of the Warburg effect. *Onco Targets Ther* 2023; 16:143–155.
23. Chen XS, Li LY, Guan YD, Yang JM, Cheng Y. Targeting the Warburg effect. *Acta Pharmacol Sin* 2016; 37:1013–1019.
24. Pavlova NN, Thompson CB. Emerging hallmarks of cancer metabolism. *Cell Metab* 2016, 23:27–47.
25. Martinez-Outschoorn UE, Peiris-Pagés M, Pestell RG, Sotgia F, Lisanti MP. Cancer metabolism: therapeutic perspective. *Nat Rev Clin Oncol* 2017; 14:11–31.
26. Batis N, Brooks JM, Payne K, et al. Lack of predictive tools for targeted therapy. *Adv Drug Deliv Rev* 2021; 176:113854.
27. Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. *Science* 2020; 368:eaaw5473.
28. Maschek G, Savaraj N, Priebe W, et al. 2-DG increases the efficacy of Adriamycin and paclitaxel. *Cancer Res* 2004;64:31–34.
29. Allen BG, Bhatia SK, Anderson CM, et al. Ketogenic diets as adjuvant cancer therapy. *Redox Biol* 2014; 2:963–970.
30. Lyssiotis CA, Kimmelman CA. Metabolic interactions in the tumor microenvironment. *Trends Cell Biol* 2017; 27:863–875.
31. El Sayed SM. Biochemical origin of the Warburg effect. *Onco Targets Ther* 2023;16:143–155.